Study on Mechanisms by which hypoxia-associated proteins regulate androgen receptor signaling

缺氧相关蛋白调节雄激素受体信号传导机制研究

基本信息

  • 批准号:
    18580127
  • 负责人:
  • 金额:
    $ 2.36万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Androgen receptor (AR) acts as a ligand-activated transcription factor that regulates the expression of genes involved in prostate development and tumorigenesis. Coactivators bind to AR and enhance the transcriptional activity of AR, indicating that coactivators play an important role in AR transactivation as a key factor. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is highly expressed in metastatic prostate cancer cells and up-regulated by hypoxia in which cancer cells grow. I have identified that GAPDH acts as an AR coactivator. GAPDH enhanced AR transactivation and formed a protein complex with AR in both cytosol and nucleus. Furthermore, RanBP10 shares high similarity with RanBPM that is a well-established AR coactivator. RanBP10 enhanced the ligand-dependent AR transactivation and formed a complex with AR. RanBP10 was highly expressed in AR-positive prostate cancer cells, whereas RanBPM was abundant in non-prostate cancer cells. RanBP10 was mostly co-localized with RanBPM thr … More oughout the cytoplasm and nucleus and formed a protein complex with itself or RanBPM, suggesting that RanBP10 enhances AR transactivation as a homo-oligomer or a hetero-oligomer with RanBPM Next, because plant-based dietary factors may have chemopreventive effects on human carcinogenesis, I have focused on the role of resveratrol, which inhibits the function of the AR in androgen-dependent prostate cancer cells. Resveratrol repressed the transcriptional activities of a mutant AR lacking the ligand-binding domain, a constitutive active form of AR, and wild-type AR, indicating that resveratorol does not inhibit AR transactivation through binding to the ligand-binding domain. The half life of AR protein was approximately 4 h in resveratrol-treated AR-positive prostate cancer cells, compared to approximately 13 h in control cells, indicating that resveratrol down-regulates AR protein through a post-translational mechanism and suggest that inhibitory effect of resveratrol on AR function is partly attributable to a decrease in the post-translational AR level. Less
雄激素受体(AR)作为一种配体激活的转录因子,调节前列腺发育和肿瘤发生相关基因的表达。辅激活因子与AR结合并增强AR的转录活性,表明辅激活因子作为关键因子在AR转录激活中起重要作用。甘油醛-3-磷酸脱氢酶(GAPDH)在转移性前列腺癌细胞中高度表达,并受癌细胞生长的缺氧上调。我已经确定GAPDH作为AR辅激活剂。GAPDH可增强AR的反式激活,并在胞浆和细胞核中与AR形成蛋白复合物。此外,RanBP 10与RanBPM具有高度相似性,RanBPM是一种公认的AR共激活剂。RanBP 10增强配体依赖性AR反式激活并与AR形成复合物。RanBP 10在AR阳性前列腺癌细胞中高度表达,而RanBPM在非前列腺癌细胞中丰富。RanBP 10与RanBPM的共定位主要发生在细胞膜上。 ...更多信息 从细胞质和细胞核中排出,并与自身或RanBPM形成蛋白质复合物,这表明RanBP 10作为同源寡聚体或与RanBPM的异源寡聚体增强AR反式激活。接下来,由于植物性饮食因子可能对人类癌发生具有化学预防作用,我将重点放在白藜芦醇的作用上,它抑制雄激素依赖性前列腺癌细胞中AR的功能。白藜芦醇抑制缺乏配体结合结构域的突变型AR(AR的组成性活性形式)和野生型AR的转录活性,表明白藜芦醇不通过与配体结合结构域结合来抑制AR反式激活。白藜芦醇处理的AR阳性前列腺癌细胞中AR蛋白的半衰期约为4小时,而对照细胞中约为13小时,表明白藜芦醇通过翻译后机制下调AR蛋白,并表明白藜芦醇对AR功能的抑制作用部分归因于翻译后AR水平的降低。少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells
  • DOI:
    10.1074/jbc.m610724200
  • 发表时间:
    2007-08-03
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Harada, Naoki;Yasunaga, Ryoko;Nakano, Yoshihisa
  • 通讯作者:
    Nakano, Yoshihisa
Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells
RanBP10 はアンドロゲン受容体のコアクチベーターとして機能する
RanBP10 作为雄激素受体的共激活剂发挥作用
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Naoki;HARADA;横山 剛士
  • 通讯作者:
    横山 剛士
Abnormal increase in the expression level of proliferation cell nuclear antigen (PCNA) in the liver and hepatic injury in rats with dietary cobalamin deficiency
膳食钴胺素缺乏大鼠肝脏增殖细胞核抗原(PCNA)表达水平异常升高及肝损伤
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Naoki;HARADA;Motoyuki NAKAO
  • 通讯作者:
    Motoyuki NAKAO
「研究成果報告書概要(和文)」より
摘自《研究结果报告摘要(日文)》
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kawauchi;et. al.;Nishimura et al.;Dezawa et al.;Yoshizawa et al.;星野 幹雄;星野 幹雄
  • 通讯作者:
    星野 幹雄
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMAJI Ryoichi其他文献

YAMAJI Ryoichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMAJI Ryoichi', 18)}}的其他基金

Effects of estrogen and phytoestrogen on myogenesis
雌激素和植物雌激素对肌生成的影响
  • 批准号:
    23580182
  • 财政年份:
    2011
  • 资助金额:
    $ 2.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on the mechanisms by which functional foods regulate androgen receptor function
功能食品调节雄激素受体功能的机制研究
  • 批准号:
    20580141
  • 财政年份:
    2008
  • 资助金额:
    $ 2.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 2.36万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 2.36万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 2.36万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 2.36万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 2.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了